On October 2, ImmunityBio, Inc. rose 10.13% in regular trading, trading at $10.2101 USD/share, with Turnover of $41.80 million.

Within the Biotechnology sector where ImmunityBio, Inc. belongs, the overall sector performance was weak. Among individual stocks, Moderna down 0.62%, Amgen down 0.65%, AbbVie down 0.18%, Gilead Sciences down 0.98%, Natera up 0.34%.

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines that harness and amplify the immune system to defeat cancers and infectious diseases. The company offers immunotherapy and cell therapy platforms including antibody cytokine fusion protein N-803, vaccine technologies, natural killer cells, and related modalities. Its therapeutic pipeline includes Phase II and III clinical trials targeting bladder, pancreatic, and lung cancers.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)